HC Wainwright Analysts Increase Earnings Estimates for BCYC

Bicycle Therapeutics plc (NASDAQ:BCYC) – Analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a report issued on Monday, December 16th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.93) per share for the quarter, up from their previous estimate of ($0.99). HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.49) EPS and FY2028 earnings at ($2.12) EPS.

Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. JMP Securities dropped their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. B. Riley lowered their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $35.25.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $15.31 on Thursday. Bicycle Therapeutics has a twelve month low of $12.17 and a twelve month high of $28.67. The firm has a market cap of $1.06 billion, a PE ratio of -4.65 and a beta of 0.86. The firm’s 50 day moving average price is $22.45 and its two-hundred day moving average price is $22.66.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm’s quarterly revenue was down 50.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.26) EPS.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker bought 500,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were purchased at an average price of $15.34 per share, for a total transaction of $7,670,000.00. Following the acquisition, the director now directly owns 9,995,274 shares of the company’s stock, valued at $153,327,503.16. The trade was a 5.27 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the sale, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,840 shares of company stock worth $259,128. 8.50% of the stock is currently owned by insiders.

Institutional Trading of Bicycle Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after acquiring an additional 1,038 shares during the period. L & S Advisors Inc raised its stake in Bicycle Therapeutics by 2.4% during the 3rd quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after purchasing an additional 1,400 shares during the last quarter. Assetmark Inc. bought a new stake in Bicycle Therapeutics in the 3rd quarter valued at $34,000. China Universal Asset Management Co. Ltd. grew its position in Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after purchasing an additional 2,918 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Bicycle Therapeutics by 0.6% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after purchasing an additional 4,976 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.